Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13502694 | 0.79 | CTSB (0.36) | CYP4F2CYP4A11CTSBCTSSCTSL | |
| SCHEMBL4764313 | 0.79 | CNR2 (0.42) | CYP4F2CYP4A11CTSBCTSSCTSL | |
| SCHEMBL5112211 | 0.77 | CNR2 (0.36) | CTSBCTSSCTSLCNR2CXCR2 | |
| SCHEMBL5674430 | 0.76 | SLC18A2 (0.42) | CTSBCTSSCTSLCNR2CXCR2 | |
| SCHEMBL5110701 | 0.74 | EPHX2 (0.49) | CYP4F2CYP4A11CTSBCTSSCTSL | |
| SCHEMBL5138861 | 0.74 | CNR2 (0.33) | CNR2CXCR2SLC18A2LPAR1 | |
| SCHEMBL8485391 | 0.72 | CNR2 (0.39) | CYP4F2CYP4A11CTSBCTSSCTSL | |
| SCHEMBL9671904 | 0.72 | SPHK1 (0.48) | CYP4F2CYP4A11CTSBCTSSCTSL | |
| SCHEMBL10594469 | 0.72 | CTSB (0.38) | CYP4F2CYP4A11CTSBCTSSCTSL | |
| SCHEMBL19782337 | 0.71 | MEN1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342027-B2 | 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2008-03-11 | — | — | US | disclosed |
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 2005-10-20 | — | — | US | disclosed |
| WO-2004011457-A1 | 1-PHENYLPIPERIDIN-3-ONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234057-A1 | 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof | CTRL, PRCP, CLPP | CYP4F2 678/4885CYP4A11 612/4885CTSB 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.